Harvard Health Blog

Promising results for a targeted drug in advanced prostate cancer

Charlie Schmidt, Editor, Harvard Medical School Annual Report on Prostate Disease Itís well known that defective BRCA genes can increase a womanís chances of developing breast, ovarian, and other cancers. But these same gene changes can also increase a manís risk of dying from prostate cancer. Now, a new study published in The New England Journal o f Medicine has shown that men with prostate cancer who test positive for BRCA mutations can benefit…

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In